Effect of a dipeptidyl peptidase-iv inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Lim, Soo ^a,b   Choi, Sung Hee ^a,b   Shin, Hayley ^c   Cho, Bong Jun ^a   Park, Ho Seon ^b   Ahn, Byung Yong ^b   Kang, Seon Mee ^a,b   Yoon, Ji Won ^a,b   Jang, Hak Chul ^a,b   Kim, Young Bum ^d   Park, Kyong Soo ^b,e  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CASPASE 3; GELATINASE A; GELATINASE B; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; PLACEBO; SITAGLIPTIN; SMALL INTERFERING RNA; C REACTIVE PROTEIN; CCL2 PROTEIN, RAT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAROTID ARTERY INJURY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE METABOLISM; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; NEOINTIMA; NICK END LABELING; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RESTENOSIS; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; ANIMAL; BLOOD; CAROTID ARTERY; CYTOLOGY; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; INJURY; INTIMA; ORAL DRUG ADMINISTRATION; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOLOGY; VASCULAR SMOOTH MUSCLE;

RATTUS;

ADIPONECTIN; ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CHEMOKINE CCL2; CORONARY RESTENOSIS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRAZINES; RATS; RATS, INBRED OLETF; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA;

EID: 84859502281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035007     Document Type: Article

References (45)

1. Buteau J, Foisy S, Joly E, Prentki M, (2003) Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-32.
2. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, et al. (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47: 806-15.
3. Drucker DJ, (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26: 2929-40.
4. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, et al. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275-86.
5. Lambeir AM, Durinx C, Scharpe S, De M, I, (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40: 209-94.
6. Holst JJ, (2003) Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv Exp Med Biol 524: 263-79.
7. Drucker DJ, (2003) Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 12: 87-100.
8. Ristic S, Byiers S, Foley J, Holmes D, (2005) Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 7: 692-8.
9. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, et al. (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89: 2078-84.
10. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, et al. (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90: 4888-94.
11. Rodriguez AE, Maree AO, Mieres J, Berrocal D, Grinfeld L, et al. (2007) Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J 28: 2118-25.
12. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP, (2010) DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients with Coronary Artery Disease. Circ Cardiovasc Imaging.
13. Yoon JS, Lee HW, (2011) Understanding the cardiovascular effects of incretin. Diabetes Metab J 35: 437-43.
14. Derosa G, D'Angelo A, Tinelli C, Devangelio E, Consoli A, et al. (2007) Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 33: 129-34.
15. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, et al. (2003) Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23: 283-8.
16. Maxwell PR, Timms PM, Chandran S, Gordon D, (2001) Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 18: 777-80.
17. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, et al. (2005) Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54: 534-9.
18. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, et al. (2008) Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 295: F1485-F1494.
19. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-7.
20. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, et al. (2007) Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 282: 10117-31.
21. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, et al. (2004) Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 44: 904-13.
22. Clowes AW, Reidy MA, Clowes MM, (1983) Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 49: 327-33.
23. Ansari B, Coates PJ, Greenstein BD, Hall PA, (1993) In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170: 1-8.
24. Lavrik IN, Golks A, Krammer PH, (2005) Caspases: pharmacological manipulation of cell death. J Clin Invest 115: 2665-72.
25. Tanaka H, Sukhova G, Schwartz D, Libby P, (1996) Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblast growth factor. Arterioscler Thromb Vasc Biol 16: 12-8.
26. Newby AC, Zaltsman AB, (2000) Molecular mechanisms in intimal hyperplasia. J Pathol 190: 300-9.
27. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA, (1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75: 539-45.
28. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, et al. (1994) Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75: 181-9.
29. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, et al. (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215.
30. Nystrom T, Gonon AT, Sjoholm A, Pernow J, (2005) Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125: 173-7.
31. Vila Petroff MG, Egan JM, Wang X, Sollott SJ, (2001) Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 89: 445-52.
32. Moreno PR, Bernardi VH, Lopez-Cuellar J, Newell JB, McMellon C, et al. (1996) Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 94: 3098-102.
33. Welt FG, Edelman ER, Simon DI, Rogers C, (2000) Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol 20: 2553-8.
34. Moreno PR, Fallon JT, Murcia AM, Leon MN, Simosa H, et al. (1999) Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. J Am Coll Cardiol 34: 1045-9.
35. Rogers C, Welt FG, Karnovsky MJ, Edelman ER, (1996) Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 16: 1312-8.
36. Mori E, Komori K, Yamaoka T, Tanii M, Kataoka C, et al. (2002) Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 105: 2905-10.
37. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY, (2000) Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75: 43-7.
38. Nagase H, Woessner JF Jr, (1999) Matrix metalloproteinases. J Biol Chem 274: 21491-4.
39. Falk E, Shah PK, Fuster V, (1995) Coronary plaque disruption. Circulation 92: 657-71.
40. Galis ZS, Sukhova GK, Lark MW, Libby P, (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94: 2493-503.
41. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K, (2001) Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 14: 475-86.
42. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, et al. (2002) Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 90: 1167-72.
43. Pasceri V, Willerson JT, Yeh ET, (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-8.
44. Ferns GA, Avades TY, (2000) The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 81: 63-88.
45. Liu H, Hu Y, Simpson RW, Dear AE, (2008) Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression. J Endocrinol 196: 57-65.